Jonathan Chang
Stock Analyst at Leerink Partners
(0.63)
# 3,858
Out of 4,870 analysts
86
Total ratings
30.14%
Success rate
-19.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Upgrades: Outperform | $27 | $20.68 | +30.56% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $31.12 | +137.79% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $4.42 | +149.15% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $16.61 | +207.04% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $4.33 | +1,632.10% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $9.23 | +268.36% | 9 | Dec 7, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.23 | +591.56% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $40.04 | -25.07% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.32 | +809.09% | 8 | Aug 9, 2022 | |
| MRSN Mersana Therapeutics | Maintains: Outperform | $13 → $14 | $0.34 | +4,010.39% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $5.42 | +380.15% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $36.01 | +163.82% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.24 | +1,137.62% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $5.87 | +377.41% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $8.40 | +530.95% | 7 | Aug 5, 2021 |
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $20.68
Upside: +30.56%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $31.12
Upside: +137.79%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $4.42
Upside: +149.15%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $16.61
Upside: +207.04%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $4.33
Upside: +1,632.10%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $9.23
Upside: +268.36%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.23
Upside: +591.56%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $40.04
Upside: -25.07%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.32
Upside: +809.09%
Mersana Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $0.34
Upside: +4,010.39%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $5.42
Upside: +380.15%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $36.01
Upside: +163.82%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.24
Upside: +1,137.62%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $5.87
Upside: +377.41%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $8.40
Upside: +530.95%